These results suggested that although immunotherapy is deemed unsuitable for patients with papillary carcinoma, they have the potential to be benefit from treatment with ERBB3/ERBB4 kinase inhibitors. This evidence concerns the gene ERBB3 and thyroid gland papillary carcinoma.